Clinical Trial Update: Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated Modified FOLFOX6 with or without sorafenib in stage IV metastatic colorectal cancer; results were completed and posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-03-20